Moving towards a precision approach for prevention of severe COVID-19 – authors' reply

Moving towards a precision approach for prevention of severe COVID-19 – authors' reply

Bibliographic Details
Main Authors:	Agrawal, U, Robertson, C, Sheikh, A
Format:	Journal article
Language:	English
Published:	Elsevier 2023

Similar Items

Author’s Reply—Is it really COVID-19?
by: David Chang, MD, et al.
Published: (2020-07-01)

Authors' reply
by: Madhu Sudan Agrawal, et al.
Published: (2017-01-01)

Authors’ Reply: Vaccination, payment, and COVID-19
by: Jelena Dotlic, et al.
Published: (2021-11-01)

Author′s reply
by: Agrawal Vinay
Published: (2010-01-01)

Author′s reply
by: Agrawal Vinay
Published: (2010-01-01)

Circumcision for HIV Prevention: Authors' Reply.
by: James G Kahn, et al.
Published: (2007-03-01)

Perceived susceptibility, severity, and reinfection of COVID-19 may influence vaccine acceptance-Authors’ reply
by: Giao Huynh, et al.
Published: (2021-01-01)

Azithromycin for mild-to-moderate COVID-19: author's reply
by: Hinks, TSC, et al.
Published: (2021)

Azithromycin for mild-to-moderate COVID-19 - Authors' reply
by: Hinks, TSC
Published: (2021)

WHO COVID-19 therapeutic guidelines – authors' reply
by: White, NJ, et al.
Published: (2021)

Moving beyond dashboards to generate data for public good—Authors’ reply
by: Chander Prakash Yadav, et al.
Published: (2022-10-01)

Author reply to letter
by: Lukas U. Zimmerli
Published: (2015-06-01)

Severity of illness and the weekend effect - Authors' reply.
by: Walker, A, et al.
Published: (2017)

Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's reply
by: Djillali Annane, et al.
Published: (2021-05-01)

Authors's reply to "Preventing atelectasia at robotic surgery"
by: Menekse Oksar, et al.

HIV treatment-as-prevention research: authors' reply.
by: Till Bärnighausen, et al.
Published: (2015-03-01)

High-dose budesonide for early COVID-19 - Authors' reply
by: Hobbs, FDR, et al.
Published: (2021)

Author's reply: COVID‐19 vaccine in liver transplant recipients
by: Atsuyoshi Mita, et al.
Published: (2024-03-01)

Workup of cerebral involvement in patients with COVID-19 – authors’ reply
by: Chi-Sheng Chen, et al.
Published: (2023-05-01)

Author reply to Letters to the Editor “COVID-19 pneumonia in Taiwan”
by: Shao-Chung Cheng, et al.
Published: (2020-05-01)

Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
by: Pablo Guisado-Vasco, et al.
Published: (2021-01-01)

Author's Reply: Towards More Informative Maps
by: Heiko Narrog
Published: (2010-01-01)

Reply from the authors [12]
by: Kuker, W, et al.
Published: (2006)

Towards precision medicine: Omics approach for COVID-19
by: Xiaoping Cen, et al.
Published: (2023-04-01)

Artesunate for severe malaria in African children - Authors' reply
by: Dondorp, A, et al.
Published: (2011)

Efficacy of MP1032 in hospitalised patients with COVID-19— authors’ reply
by: Petra Sager, et al.
Published: (2024-03-01)

Timing and sequence of vaccination against COVID-19 and influenza – Author's reply
by: Elisabeth A. Dulfer, et al.
Published: (2023-07-01)

COVID-19 vaccines: effectiveness and number needed to treat – Authors' reply
by: Piero Olliaro, et al.
Published: (2021-07-01)

The authors reply
by: Chapman, D, et al.
Published: (2023)

Authors' reply
by: Herbert, K, et al.
Published: (2012)

Authors' reply
by: Khan, A, et al.
Published: (2010)

Authors' reply
by: Leucht, S, et al.
Published: (2013)

The authors reply
by: Holman, R, et al.
Published: (2009)

The authors reply
by: Rahman, N, et al.
Published: (2011)

The authors' reply
by: Hobbs, F, et al.
Published: (2011)

The authors reply
by: Burdmann, E, et al.
Published: (2017)

Authors' reply
by: White, P, et al.
Published: (2011)

The authors reply
by: Collins, R, et al.
Published: (2009)

Authors' reply.
by: Garety, P, et al.
Published: (2014)

The authors reply
by: Holman, R, et al.
Published: (2008)